Active substance
Indometacin
- SFDA 19
- US FDA 75
- Health Canada 7
- US price lines 3
- NHS prices 3
- WHO EML 1
- Safety 9
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| INDOMIN CAP 25MG | 25 mg | Capsule · Oral use | 20 Blister | SAR 2.25 | Generic · Prescription | Hikma Pharmaceuticals PLC | Valid |
| ROTHACIN 100MG SUPPOSITORIES | 100 mg | Suppository · Rectal use | 10 Blister | SAR 13.20 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| INDOCID 100MG SUPPOSITORIES | 100 mg | Suppository · Rectal use | 10 Blister | SAR 25.35 | Generic · Prescription | Algorithm SAL | Suspended |
| CONFORTID 25MG CAPS | 25 mg | Capsule · Oral use | 24 Blister | SAR 11.20 | Generic · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| CONFORTID 50MG SUPPOSITORY | 50 mg | Suppository · Rectal use | 10 Blister | SAR 15.80 | Generic · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| CONFORTID INJ I.V 50MG | 50 mg/ml | Solution · Intravenous use | 10 Vial | SAR 277.85 | NCE · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| CONFORTID INJ I.V 50MG | 50 mg/ml | Solution · Intravenous use | 3 Vial | SAR 100.05 | NCE · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| CONFORTID SUPPOSITORIES 100 MG. | 100 mg | Suppository · Rectal use | 10 Blister | SAR 21.55 | Generic · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| CONFORTID SYRUP 5MG-ML | 5 mg/ml | Syrup · Oral use | 1 Bottle | SAR 23.25 | NCE · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| INDOCID | 75 mg | Capsule · Oral use | 30 Blister | SAR 26.50 | NCE · Prescription | MERCK SHARP & DOHME | Withdrawn by MAH · Not Marketed |
| INDOCID 100 MG SUPP | 100 mg | Suppository · Rectal use | 10 Blister | SAR 22.05 | Generic · Prescription | Algorithm SAL | Withdrawn by MAH · Not Marketed |
| INDOCID 100 MG SUPP | 100 mg | Suppository · Rectal use | 5 Blister | SAR 12.75 | NCE · Prescription | MERCK SHARP & DOHME | Withdrawn by MAH · Not Marketed |
| INDOCID 25 | 25 mg | Capsule · Oral use | 30 Blister | SAR 13.95 | NCE · Prescription | MERCK SHARP & DOHME | Withdrawn by MAH · Not Marketed |
| INDOGESIC CAP 25MG | 25 mg | Capsule · Oral use | 30 Blister | SAR 3.45 | Generic · Prescription | DAR ALDAWA | Withdrawn by MAH · Not Marketed |
| INDOMETHACIN CAPS 25MG | 25 mg | Capsule · Oral use | 30 Blister | SAR 7.40 | Generic · Prescription | MISR COMPANY FOR MEDICAL PRODUCTS | Withdrawn by regulatory authority · Not Marketed |
| INDOMIN 100MG SUPP | 100 mg | Suppository · Rectal use | 6 Blister | SAR 2.40 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| METHACIN CAPS. 25MG | 25 mg | Capsule · Oral use | 24 Blister | SAR 2.45 | Generic · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Withdrawn by MAH · Not Marketed |
| METHACIN SUPP. 100 MG | 100 mg | Suppository · Rectal use | 5 Blister | SAR 1.90 | Generic · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Withdrawn by MAH · Not Marketed |
| ROTHACIN CAPS 25 MG | 25 mg | Capsule · Oral use | 30 Blister | SAR 9.75 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE PANCREATITIS-PAIN MANAGEMENT; ANKYLOSING SPONDYLITIS; CHRONIC PANCREATITIS; DENTAL ABSCESS-DENTAL PAIN; ENDOMETRIOSIS; ENTEROPATHIC ARTHROPATHIES, UNSPECIFIED SITE REACTIVE ARTHROPATHY, UNSPECIFIED; EPIDERMOLYSIS BULLOSA; GOUT; JUVENILE IDIOPATHIC ARTHRITIS (JIA); LOW BACK PAIN; MENSTRUAL DISORDERS; MUCOSAL ULCERATION-SUPPORTIVE AGENTS; OSTEOARTHRITIS; PAIN MANAGEMENT IN CANCER PATIENTS; POSTOPERATIVE PAIN; PSORIATIC ARTHRITIS; RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS; SICKLE CELL DISEASE - PAIN MANAGEMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| INDOMETHACIN | 50MG; 25MG | capsule · oral | CHARTWELL MOLECULES | Prescription | 6 Aug 1984 |
| INDOCIN | 25MG/5ML | suspension · oral | COSETTE | Prescription | 10 Oct 1985 |
| INDOMETHACIN | 50MG | capsule · oral | CHARTWELL MOLECULES | Prescription | 5 Mar 1986 |
| INDOMETHACIN | 25MG | capsule · oral | SANDOZ | Prescription | 29 Apr 1987 |
| INDOMETHACIN | 50MG | capsule · oral | SANDOZ | Prescription | 29 Apr 1987 |
| INDOMETHACIN | 50MG | suppository · rectal | COSETTE | Prescription | 31 Aug 1992 |
| INDOMETHACIN | 75MG | capsule, extended release · oral | AVANTHI INC | Prescription | 6 Mar 2009 |
| INDOMETHACIN | EQ 1MG BASE/VIAL | injectable · injection | FRESENIUS KABI USA | Prescription | 17 Mar 2010 |
| INDOMETHACIN | 25MG; 50MG | capsule · oral | ZYDUS LIFESCIENCES | Prescription | 15 Nov 2010 |
| INDOMETHACIN | 75MG | capsule, extended release · oral | CHARTWELL RX | Prescription | 30 Nov 2010 |
| INDOMETHACIN | 75MG | capsule, extended release · oral | AMNEAL PHARMS | Prescription | 1 Dec 2010 |
| INDOMETHACIN | 25MG; 50MG | capsule · oral | GLENMARK PHARMS LTD | Prescription | 22 Dec 2010 |
| INDOMETHACIN | 25MG; 50MG | capsule · oral | HETERO LABS LTD III | Prescription | 12 Apr 2011 |
| INDOMETHACIN | 75MG | capsule, extended release · oral | HETERO LABS LTD III | Prescription | 28 Sep 2012 |
| INDOMETHACIN | 75MG | capsule, extended release · oral | NOVAST LABS | Prescription | 8 May 2017 |
| INDOMETHACIN | 75MG | capsule, extended release · oral | GLENMARK PHARMS LTD | Prescription | 22 Jun 2017 |
| INDOMETHACIN | 75MG | capsule, extended release · oral | ZYDUS PHARMS | Prescription | 25 Sep 2017 |
| INDOMETHACIN | 50MG | suppository · rectal | ZYDUS LIFESCIENCES | Prescription | 2 Aug 2023 |
| INDOMETHACIN | 25MG/5ML | suspension · oral | NOVITIUM PHARMA | Prescription | 12 Jan 2024 |
| INDOMETHACIN | 50MG | suppository · rectal | HIKMA PHARMS | Prescription | 19 Nov 2024 |
| INDOMETHACIN | 50MG | suppository · rectal | AMNEAL | Prescription | 24 Feb 2025 |
| INDOMETHACIN | 50MG | suppository · rectal | ANNORA PHARMA | Prescription | 3 Jul 2025 |
| INDOCIN | 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | ZYLA LIFE SCIENCES | Discontinued | 10 Jun 1965 |
| INDOCIN SR | 75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule, extended release · oral | ZYLA | Discontinued | 23 Feb 1982 |
| INDOMETHACIN | 25MG; 50MG | capsule · oral | RISING | Discontinued | 20 Apr 1984 |
50 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AURO-INDOMETHACIN | 02499223 | 50 MG | CAPSULE · ORAL | AURO PHARMA INC |
| MINT-INDOMETHACIN | 02461536 | 50 MG | CAPSULE · ORAL | MINT PHARMACEUTICALS INC |
| MINT-INDOMETHACIN | 02461811 | 25 MG | CAPSULE · ORAL | MINT PHARMACEUTICALS INC |
| ODAN-INDOMETHACIN | 02231799 | 50 MG / SUP | SUPPOSITORY · RECTAL | ODAN LABORATORIESLTD |
| ODAN-INDOMETHACIN | 02231800 | 100 MG / SUP | SUPPOSITORY · RECTAL | ODAN LABORATORIESLTD |
| TEVA-INDOMETHACIN | 00337420 | 25 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
| TEVA-INDOMETHACIN | 00337439 | 50 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | INDOMETHACIN 25 MG CAPSULE | $0.09341 | per EA | 23 Sep 2026 |
| US NADAC | INDOMETHACIN 50 MG CAPSULE | $0.13013 | per EA | 23 Sep 2026 |
| US NADAC | INDOMETHACIN ER 75 MG CAPSULE | $0.20992 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Indometacin 100mg suppositories | £17.61 | 10 suppository | 1 Oct 2026 |
| NHS Drug Tariff | Indometacin 25mg capsules | £19.30 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Indometacin 50mg capsules | £34.72 | 28 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 22.7. Medicines administered to the neonate [c] · complementary
Therapeutic equivalent to ibuprofen for Patent arterial duct
Safety signals and safety-related labeling changes
- US FDA 21 Nov 2024 INDOCIN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 INDOCIN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 INDOCIN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 INDOCIN SR — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 INDOMETHACIN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 INDOMETHACIN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 INDOMETHACIN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Apr 2021 TIVORBEX — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 26 Mar 2021 INDOCIN — safety-related labeling change
Labeling sections changed: Adverse Reactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.